Clinical Trial Search Results for "PRINCIPLE-TIMI 44"

Wiviott, S. D., Trenk, D., Frelinger, A. L., O'Donoghue, M., Neumann, F. J., Michelson, A. D., Angiolillo, D. J., Hod, H., Montalescot, G., Miller, D. L., Jakubowski, J. A., Cairns, R., Murphy, S. A., McCabe, C. H., Antman, E. M., Braunwald, E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation. 2007;116(25):2923-32. Abstract

Frelinger, A. L., 3rd, Michelson, A. D., Wiviott, S. D., Trenk, D., Neumann, F. J., Miller, D. L., Jakubowski, J. A., Costigan, T. M., McCabe, C. H., Antman, E. M., Braunwald, E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44 Thrombosis and haemostasis. 2011;106(2):219-26. Abstract

O'Donoghue, M. L., Mallat, Z., Morrow, D. A., Benessiano, J., Sloan, S., Omland, T., Solomon, S. D., Braunwald, E., Tedgui, A., Sabatine, M. S. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease Clinical chemistry. 2011;57(9):1311-7. Abstract